Rezolute, Inc. (NASDAQ:RZLT) is a biopharmaceutical company focused on developing therapies for rare diseases. The company recently faced a significant setback with its Phase 3 sunRIZE study, which aimed to evaluate the efficacy of its drug, ersodetug, for treating congenital hyperinsulinism (HI). This condition causes dangerously low blood sugar levels, and the trial's failure has impacted the company's stock performance.
On December 11, 2025, Wedbush set a price target of $1 for RZLT, while the stock was trading at $1.245. This target suggests a potential decrease of approximately -19.68%. The stock's decline is largely attributed to the disappointing results of the sunRIZE study, which saw the stock plummet nearly 90% to $1.15. The trial did not meet its primary endpoint, as the highest dose of ersodetug only achieved a 45% reduction in hypoglycemia events, not statistically significant compared to the placebo group's 40% reduction.
The trial also failed to meet its key secondary endpoint, which measured the change in average daily percent time in hypoglycemia. The top dose showed a 25% reduction, while the placebo group experienced a 5% increase. Despite these setbacks, Rezolute reported that target drug concentrations were achieved across all age groups, and safety observations were generally favorable, although two participants experienced serious hypersensitivity reactions.
Currently, RZLT is priced at $1.29, reflecting a significant decrease of 88.21% from its previous value. The stock has fluctuated between a low of $1.07 and a high of $1.41 today. Over the past year, it reached a high of $11.46 and a low of $1.07. The market capitalization of RZLT stands at approximately $119.62 million, with a trading volume of 91.55 million shares.
